Arcturus Therapeutics HoldingsARCT +5.81%56 3-Year ROIIC % is 84.72 as of Dec. 2025, which is 793% above its 10-year median of 9.49. GuruFocus rates ARCT with a GF Score™ of 56/100 and a GF Value™ of $4.13 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,320 Biotechnology companies, Arcturus Therapeutics Holdings ranks better than 76.67% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Arcturus Therapeutics Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 84.72%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Arcturus Therapeutics Holdings 3-Year ROIIC % Related Terms
Arcturus Therapeutics Holdings 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -76.26 (Dec. 2025) - 10.6950591 (Dec. 2022) )
/
( 49.11 (Dec. 2025) - 151.747 (Dec. 2022) )
=
-86.9550591
/
-102.637
=
84.72%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Arcturus Therapeutics Holdings (ARCT) has a 3-Year ROIIC % of 84.72 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Arcturus Therapeutics Holdings and its competitors. This is 793% above median its historical median of 9.49. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #308 out of 1320 companies in the Biotechnology industry, placing it in the top 23.3%.
Is Arcturus Therapeutics Holdings' 3-Year ROIIC % too high?
Arcturus Therapeutics Holdings' current 3-Year ROIIC % of 84.72 is 793% above median its 10-year median of 9.49. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #308 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' 3-Year ROIIC % compare to MDWD and UNCY?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #308 out of 1320 companies for 3-Year ROIIC %. This places Arcturus Therapeutics Holdings in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current 3-Year ROIIC % is 84.72, which is 793% above median its own 10-year median of 9.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.13, compared to a current price of $7.27 — trading 76% above its estimated fair value. The current 3-Year ROIIC % is 84.72, which is 793% above median its 10-year median of 9.49. Arcturus Therapeutics Holdings' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current 3-Year ROIIC % is 84.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $7.27 is trading 76% above its estimated GF Value™ of $4.13.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
3-Year ROIIC %: 84.72 (793% above median its 10-year median of 9.49)
GF Value™: $4.13 vs. price of $7.27 (76% above fair value)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
56GF Score
Get the complete analysis for ARCT
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
